Is ebglyss an injection or a topical cream for eczema?

Is Ebglyss an injection or a topical cream for eczema?

Ebglyss is given as a subcutaneous injection, not a cream. Patients or caregivers inject it under the skin every four weeks after the first two doses are given two weeks apart.

How is the injection administered?

The drug comes in a pre-filled syringe or pen. You can give it at home once trained, or receive it at a clinic. Injection sites include the thigh, abdomen, or upper arm, rotating locations to avoid irritation.

What happens if someone tries to use it like a cream?

Ebglyss is not formulated for skin application. Applying it topically would not deliver the active antibody into the bloodstream where it works, so it would provide no benefit for eczema.

Why is an injection used instead of a cream?

The medicine is a monoclonal antibody that blocks IL-13 signaling throughout the body. Only systemic delivery reaches the deeper immune pathways driving moderate-to-severe eczema; surface creams cannot do this.

When does patent protection end?

The main U.S. composition-of-matter patent for lebrikizumab (Ebglyss) expires in 2032, though additional method-of-use and formulation patents may extend exclusivity further [1]. DrugPatentWatch.com tracks these dates and any new filings.

Are there topical alternatives already available?

Yes. Several non-steroidal creams and ointments (such as crisaborole, ruxolitinib, and topical JAK inhibitors) are approved for eczema and work directly on the skin without injections.

Who makes Ebglyss?

Eli Lilly developed and markets Ebglyss. The company also sells the competing injectable Dupixent in partnership with Regeneron.

[1] https://www.drugpatentwatch.com